Search the Newsreel

Sagility shares surge 8%; brokerages retain 'Buy' despite Q1 revenue dip QoQ; check target prices

Agilysys raises full-year 2027 revenue range to $368M-$373M

Agile Group Holdings Limited Revenue Breakdown – HKEX:3383

Is Agilent Technologies (A) Undervalued Following Its FDA Approval For OPDIVO Companion Diagnostics?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Agilent Technologies (A) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for …

Earnings To Watch: Agilysys (AGYS) Reports Q2 Results Tomorrow

Agilysys (AGYS), a hospitality software provider, is set to report its Q2 results, with the market anticipating a 12.4% year-on-year revenue growth. The company previously exceeded revenue and EBITDA estimates in the last quarter, reporting $82.95 million, an 11.7% increase year-on-year. Despite positive sentiment …

Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test

In July 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb's OPDIVO and …

What to Expect From Agilent Technologies' Q3 2026 Earnings Report

Agilent Technologies (A) is expected to report its fiscal Q3 2026 results soon, with analysts forecasting an adjusted EPS of $1.48, an 8% increase year-over-year. The company has a "Moderate Buy" rating from analysts, with an average price target of $158.21, suggesting a potential …

Agilysys, Inc. Revenue Breakdown – NASDAQ:AGYS

Agilysys, Inc. (NASDAQ: AGYS) recorded total revenue of $319.31 million USD last year. Its top-performing segment, Subscription and Maintenance, generated $205.94 million USD, an increase from $170.05 million USD the prior year. The United States market was the primary revenue driver, contributing $296.96 million …

Agilent Technologies Inc (A) Institutional Confidence

Agilent Technologies Inc (A) has an institutional shareholding score of 7.00, placing it 79th in the Healthcare Equipment & Supplies industry. Institutional investors hold 86.97% of shares, a decrease of 8.35% quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 3.52 million shares, representing 1.26% …

Agilent Technologies Inc (A) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Agilent Technologies Inc (A), listing major institutional shareholders like Vanguard and BlackRock, along with their respective proportions. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) and provides a history of institutional shareholdings over several …

AGYS|Agilysys Inc|Price:98.540|Chg%:+3.530

Agilysys Inc (AGYS) is a hospitality software company trading at $98.54, up 3.72%. The company has strong fundamentals and high growth potential, with its revenue averaging 34.47% year-on-year over the past three years. Analysts rate AGYS as a "Buy" with a target price of …

Is Agilysys (AGYS) Undervalued Or Is Its Rich P/E Already Pricing In Growth?

Agilysys (AGYS) has seen recent share price fluctuations, with a short-term dip but strong 3-month momentum. While a market narrative suggests it's undervalued with a fair value of $127.33 due to strong growth potential in cloud-native hospitality software, its current P/E of 68.9x significantly …

Agilent Technologies Inc|Price:138.570|Chg%:-1.185

This article provides a comprehensive stock analysis of Agilent Technologies Inc (A), highlighting its stable fundamentals, high growth potential, and "Fairly Valued" status within the Healthcare Equipment & Supplies industry. The company is noted for its high and stable dividend payments and a strong …

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Agilent Technologies Inc. announced it has received EU certification for its PD-L1 IHC 22C3 pharmDx test. This companion diagnostic helps identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and who may be eligible for treatment with Merck's …

Agilent Technologies Inc

Agilent Technologies Inc. (A) is highlighted as having stable fundamentals and high growth potential, with its valuation considered fairly valued within the Healthcare Equipment & Supplies industry. Analysts have rated it a "Buy" with a target price of $159.56, suggesting an expected upward trend …

Sagility Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Agilon Health, Inc. (NYSE:AGL) Receives Consensus Rating of "Hold" from Analysts

Agilon Health, Inc. (NYSE:AGL) has received a consensus "Hold" rating from fourteen research firms, with an average 12-month target price of $64.00, despite mixed recent analyst actions. The company reported better-than-expected quarterly results with EPS of $1.80 and revenue of $1.42 billion, but still …

agilon health, inc. Stock 12‑Month Price Target Raised to $73.36, Implies 39% Downside

agilon health, inc. (AGL) stock's average 12-month price target has been increased to $73.36 by 14 analysts, up from $71.57, though this still implies a 39% potential downside based on the July 22nd closing price. The consensus analyst rating remains "Hold" across 17 analysts, …

agilon health, inc. (AGL) Stock Price, News, Quote & History

This page provides comprehensive financial data, news, and history for agilon health, inc. (AGL). It includes real-time stock prices, performance charts, key statistics like market cap and P/E ratio, analyst insights, and comparisons with similar companies in the medical care facilities industry. The company, …

Agilent Technologies Inc. stock underperforms Thursday when compared to competitors despite daily gains

Agilent Technologies Inc. (A) stock rose 4.71% on Thursday, closing at $139.74, despite a down day for the broader market, with the S&P 500 and Dow Jones Industrial Average both falling. This marks the third consecutive day of gains for the stock. However, the …

Why agilon health (AGL) Shares Are Falling Today

Agilon Health (AGL) shares dropped 10.8% after Citi downgraded the stock from Neutral to Sell, citing valuation concerns following a 650% rally in 2026. The downgrade further noted risks due to Medicare Advantage plans and an investigation into potential false statements regarding medical costs. …

Citi Downgrades Agilon Health(AGL.US) to Sell Rating, Raises Target Price to $105

Citi has downgraded Agilon Health (AGL.US) to a Sell rating from a previous Buy rating. Despite the downgrade, the firm increased its target price for the company to $105. This adjustment reflects a mixed outlook from Citi on Agilon Health's stock.

Agilent stock rises on EU approval for cancer diagnostic

Agilent Technologies Inc. (NYSE:A) shares rose after receiving European Union certification for its PD-L1 IHC 22C3 pharmDx companion diagnostic for ovarian cancer. This approval allows the diagnostic to identify eligible patients for treatment with Merck’s KEYTRUDA. This is the eighth CE-marked companion diagnostic indication …

Agilysys Set to Release Q1 Earnings: Here's What to Expect

Agilysys (AGYS) is set to release its Q1 fiscal 2027 earnings on July 27, with analysts expecting a 21.2% increase in earnings per share and a 12% rise in revenues year-over-year. Despite a mixed earnings surprise history, the company anticipates record sales and profitability …

Citigroup Downgrades Agilon health to Sell From Neutral, Adjusts Price Target to $105 From $80

Citigroup has downgraded agilon health (AGL) from "Neutral" to "Sell" and adjusted its price target from $80 to $105. This news led to a decrease in agilon health's share price. The article also provides recent news headlines related to agilon health, including previous analyst …

Agilon Health | 8-K: Current report

This 8-K filing from Agilon Health is a Current Report, which is used to announce unscheduled material events or corporate changes that are important to shareholders. Without further detail, the report likely contains information about a significant event that recently occurred at the company.

Agilysys Inc (AGYS) Shares Fall 3.6% -- What GF Score of 80 Tells Investors

Agilysys Inc (AGYS) shares fell 3.6% to $97.04 but are considered "Modestly Undervalued" with a GF Value™ of $120.68, indicating a potential 19.6% upside. The company boasts a strong GF Score™ of 80/100, driven by excellent financial strength (9/10) and favorable valuation (10/10), despite …

Agilent BDR program executes 5-for-1 stock split on ratio adjustment

Agilent's BDR program in Brazil will undergo a 5-for-1 stock split, adjusting the underlying-to-BDR ratio from 1:2 to 1:10, effective August 10, 2026. This mandatory split will deliver four additional BDRs for each one held on August 7, 2026. Fractional entitlements will be paid …

Agilent Technologies (A) Stock Forecast & Analyst Ratings

This article provides an analyst consensus forecast for Agilent Technologies (A) stock, indicating an average price target that suggests a potential upside from its current trading price. It also covers recent analyst actions, including upgrades and downgrades, and summarizes the company's financial performance.

A4881169 Bond Profile — Key Metrics

This article provides key metrics for the A4881169 bond, issued by Agilent Technologies, Inc. The bond has a coupon rate of 2.75% and matures on September 15, 2029, with an outstanding amount of $500 million. Agilent Technologies is described as a company focused on …

AGYS Earnings Preview: Can Agilysys Deliver Another Record Revenue Quarter?

Agilysys (AGYS), a hospitality software company, is set to release its Q1 earnings report, with investors keen to see if it can achieve another record revenue quarter driven by sustained subscription growth, the rollout of its PMS at Marriott, and AI adoption. Despite high …

agilon CTO Girish Venkatachaliah to Depart Aug 1, 2026 with Severance and Consulting Arrangement

agilon's CTO, Girish Venkatachaliah, will depart from his role on August 1, 2026. He will receive a cash severance of $766,063 and continued equity vesting, while also providing transition consulting services until December 31, 2026. This information is based on an SEC filing from …

Sagility India slips despite 46% profit jump; Nomura trims target, retains Buy

Sagility Q1 Results: CFO Srinivas Mattapalli On 27.6% Revenue Growth, Margins & Outlook

AGL stock holds as Agilon Health revenue and loss frame the 2026 outlook

Agilon Health's (AGL) stock performance for 2026 is still being shaped by its 2025 financial results, which reported $1.52 billion in revenue but a net loss of $123.0 million, and negative adjusted EBITDA. The company's liquidity, with $401.6 million in cash equivalents, also remains …

Agilysys Drops 5.4% Amid Sector-Wide Selling

Agilysys Inc. experienced a sharp decline of 5.4% to $100.56, attributed to a broad sector-wide selloff impacting software companies rather than company-specific issues. Other related companies like FRSH and BRZE also saw drops of 3.9% and 6.5% respectively, indicating coordinated sector weakness. The synchronized …